Moleculin Biotech, Inc.
Moleculin Biotech, Inc. (MBRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mbrx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Moleculin Biotech, Inc. (MBRX) measures how much investors pay for each dollar of the company's trailing earnings. MBRX's current PE ratio of N/A is calculated by dividing its stock price of $2.47 by its TTM earnings per share of -$0.74.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Moleculin Biotech, Inc.You MBRX | $3M | N/A | — | -$0.74 |
 Adaptimmune Therapeutics plc ADAP | $75M | N/A | — | -$0.28 |
 Ainos, Inc. AIMD | $9M | N/A | — | -$3.46 |
 Apollomics, Inc. APLM | $15M | N/A | — | -$7.57 |
 Athira Pharma, Inc. ATHA | $27M | N/A | — | -$24.70 |
 BioLineRx Ltd. BLRX | $14M | N/A | — | -$0.29 |
 Citius Pharmaceuticals, Inc. CTXR | $7M | N/A | — | -$3.38 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.83 | — | |
2024-12-31 FY2024 | — | $-158.02 | — | |
2023-12-31 FY2023 | — | $-376.71 | — | |
2022-12-31 FY2022 | — | $-380.52 | — | |
2021-12-31 FY2021 | — | $-221.77 | — | |
2020-12-31 FY2020 | — | $-661.02 | — | |
2019-12-31 FY2019 | — | $-729.64 | — | |
2018-12-31 FY2018 | — | $-1031.53 | — | |
2017-12-31 FY2017 | — | $-1188.05 | — | |
2016-12-31 FY2016 | — | $-898.89 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Moleculin Biotech, Inc. (MBRX) measures how much investors pay for each dollar of the company's trailing earnings. MBRX's current PE ratio of N/A is calculated by dividing its stock price of $2.47 by its TTM earnings per share of -$0.74.
Frequently asked questions
MBRX pe ratio · 6 questionsMBRX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.47 and TTM EPS of -$0.74. Data sourced from Financial Modeling Prep via MBRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Moleculin Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09